The price of BioAge Labs Inc (NASDAQ:BIOA) shares last traded on Wall Street rose 2.36% to $6.08.
BIOA stock price is now -64.94% away from the 50-day moving average and -66.42% away from the 200-day moving average. The market capitalization of the company currently stands at $218.27M.
With the price target reduced from $40 to $5, Morgan Stanley Downgraded its rating from Overweight to Underweight for BioAge Labs Inc (NASDAQ: BIOA). On December 09, 2024, Jefferies Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $42 to quote $7, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, Pande Vijay Satyanand, Director bought 126,793 shares of the company’s stock on Oct 01 ’24. The stock was bought for $2,501,626 at an average price of $19.73. Upon completion of the transaction, the Director now directly owns 1,026,793 shares in the company, valued at $6.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 02 ’24, Director Pande Vijay Satyanand bought 67,096 shares of the business’s stock. A total of $1,323,804 was incurred on buying the stock at an average price of $19.73. This leaves the insider owning 1,093,889 shares of the company worth $6.65 million. A total of 42.93% of the company’s stock is owned by insiders.
During the past 12 months, BioAge Labs Inc has had a low of $3.85 and a high of $26.62. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 17.63, and a quick ratio of 17.63. The fifty day moving average price for BIOA is $17.7022 and a two-hundred day moving average price translates $18.302097 for the stock.
The latest earnings results from BioAge Labs Inc (NASDAQ: BIOA) was released for 2024-09-30.
